BioSyent Inc. (CVE:RX - Free Report) - Analysts at Bloom Burton boosted their FY2025 EPS estimates for BioSyent in a note issued to investors on Monday, March 17th. Bloom Burton analyst D. Martin now anticipates that the company will post earnings per share of $0.81 for the year, up from their previous forecast of $0.80. The consensus estimate for BioSyent's current full-year earnings is $0.69 per share. Bloom Burton also issued estimates for BioSyent's FY2027 earnings at $0.94 EPS.
BioSyent Trading Up 0.4 %
Shares of CVE:RX traded up C$0.05 during mid-day trading on Tuesday, reaching C$11.30. The stock had a trading volume of 3,440 shares, compared to its average volume of 4,553. The firm has a market cap of C$129.24 million, a PE ratio of 18.34 and a beta of 0.93. The firm has a 50 day simple moving average of C$11.03 and a two-hundred day simple moving average of C$11.12. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. BioSyent has a twelve month low of C$8.24 and a twelve month high of C$12.13.
Insider Buying and Selling at BioSyent
In related news, insider FAX Capital Corp. sold 112,400 shares of the firm's stock in a transaction on Monday, December 23rd. The stock was sold at an average price of C$11.28, for a total value of C$1,267,557.28. Insiders sold 112,540 shares of company stock valued at $1,269,132 in the last quarter. 33.65% of the stock is currently owned by insiders.
About BioSyent
(
Get Free Report)
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Stories
Before you consider BioSyent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioSyent wasn't on the list.
While BioSyent currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
